Literature DB >> 18173751

Familial myelodysplasia and acute myeloid leukaemia--a review.

Carolyn Owen1, Michael Barnett, Jude Fitzgibbon.   

Abstract

Familial occurrence of myelodysplasia (MDS) and/or acute myeloid leukaemia (AML) is rare but can provide a useful resource for the investigation of predisposing mutations in these myeloid malignancies. To date, examination of families with MDS/AML has lead to the detection of two culprit genes, RUNX1 and CEBPA. Germline mutations in RUNX1 result in familial platelet disorder with propensity to myeloid malignancy and inherited mutations of CEBPA predispose to AML. Unfortunately, the genetic cause remains obscure in most other reported pedigrees. Further insight into the molecular mechanisms of familial MDS/AML will require awareness by clinicians of new patients with relevant family histories.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18173751     DOI: 10.1111/j.1365-2141.2007.06909.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  61 in total

1.  Familial aggregation of acute myeloid leukemia and myelodysplastic syndromes.

Authors:  Lynn R Goldin; Sigurdur Y Kristinsson; Xueying Sharon Liang; Asa R Derolf; Ola Landgren; Magnus Björkholm
Journal:  J Clin Oncol       Date:  2011-12-12       Impact factor: 44.544

2.  GATA2 mutations lead to MDS and AML.

Authors:  R Katherine Hyde; P Paul Liu
Journal:  Nat Genet       Date:  2011-09-28       Impact factor: 38.330

3.  Genetic predisposition to myelodysplastic syndrome and acute myeloid leukemia in children and young adults.

Authors:  Daria V Babushok; Monica Bessler; Timothy S Olson
Journal:  Leuk Lymphoma       Date:  2015-12-23

4.  Germ-line GATA2 p.THR354MET mutation in familial myelodysplastic syndrome with acquired monosomy 7 and ASXL1 mutation demonstrating rapid onset and poor survival.

Authors:  Csaba Bödör; Aline Renneville; Matthew Smith; Aurélie Charazac; Sameena Iqbal; Pascaline Etancelin; Jamie Cavenagh; Michael J Barnett; Karolina Kramarzová; Biju Krishnan; András Matolcsy; Claude Preudhomme; Jude Fitzgibbon; Carolyn Owen
Journal:  Haematologica       Date:  2012-01-22       Impact factor: 9.941

Review 5.  p53-Independent, normal stem cell sparing epigenetic differentiation therapy for myeloid and other malignancies.

Authors:  Yogen Saunthararajah; Pierre Triozzi; Brian Rini; Arun Singh; Tomas Radivoyevitch; Mikkael Sekeres; Anjali Advani; Ramon Tiu; Frederic Reu; Matt Kalaycio; Ed Copelan; Eric Hsi; Alan Lichtin; Brian Bolwell
Journal:  Semin Oncol       Date:  2012-02       Impact factor: 4.929

6.  Next-generation sequencing-based multigene mutational screening for acute myeloid leukemia using MiSeq: applicability for diagnostics and disease monitoring.

Authors:  Rajyalakshmi Luthra; Keyur P Patel; Neelima G Reddy; Varan Haghshenas; Mark J Routbort; Michael A Harmon; Bedia A Barkoh; Rashmi Kanagal-Shamanna; Farhad Ravandi; Jorge E Cortes; Hagop M Kantarjian; L Jeffrey Medeiros; Rajesh R Singh
Journal:  Haematologica       Date:  2013-10-18       Impact factor: 9.941

7.  High frequency of GATA2 mutations in patients with mild chronic neutropenia evolving to MonoMac syndrome, myelodysplasia, and acute myeloid leukemia.

Authors:  Marlène Pasquet; Christine Bellanné-Chantelot; Suzanne Tavitian; Naïs Prade; Blandine Beaupain; Olivier Larochelle; Arnaud Petit; Pierre Rohrlich; Christophe Ferrand; Eric Van Den Neste; Hélène A Poirel; Thierry Lamy; Marie Ouachée-Chardin; Véronique Mansat-De Mas; Jill Corre; Christian Récher; Geneviève Plat; Françoise Bachelerie; Jean Donadieu; Eric Delabesse
Journal:  Blood       Date:  2012-12-06       Impact factor: 22.113

Review 8.  Constitutional mismatch repair deficiency and childhood leukemia/lymphoma--report on a novel biallelic MSH6 mutation.

Authors:  Tim Ripperger; Carmela Beger; Nils Rahner; Karl W Sykora; Clemens L Bockmeyer; Ulrich Lehmann; Hans H Kreipe; Brigitte Schlegelberger
Journal:  Haematologica       Date:  2009-12-16       Impact factor: 9.941

Review 9.  Genetic tests to evaluate prognosis and predict therapeutic response in acute myeloid leukemia.

Authors:  Margaret L Gulley; Thomas C Shea; Yuri Fedoriw
Journal:  J Mol Diagn       Date:  2009-12-03       Impact factor: 5.568

Review 10.  Familial myelodysplastic syndrome/acute leukemia syndromes: a review and utility for translational investigations.

Authors:  Allison H West; Lucy A Godley; Jane E Churpek
Journal:  Ann N Y Acad Sci       Date:  2014-01-27       Impact factor: 5.691

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.